Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Cash & Current Investments (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Cash & Current Investments for 6 consecutive years, with $96.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Current Investments fell 59.56% to $96.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $96.2 million, a 59.56% decrease, with the full-year FY2025 number at $96.2 million, down 59.56% from a year prior.
  • Cash & Current Investments was $96.2 million for Q4 2025 at Lexicon Pharmaceuticals, down from $116.0 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $355.6 million in Q1 2024 to a low of $96.2 million in Q4 2025.
  • A 3-year average of $204.9 million and a median of $206.6 million in 2023 define the central range for Cash & Current Investments.
  • Peak YoY movement for Cash & Current Investments: surged 235.67% in 2024, then crashed 59.56% in 2025.
  • Lexicon Pharmaceuticals' Cash & Current Investments stood at $170.0 million in 2023, then soared by 39.95% to $238.0 million in 2024, then plummeted by 59.56% to $96.2 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Cash & Current Investments are $96.2 million (Q4 2025), $116.0 million (Q3 2025), and $139.0 million (Q2 2025).